Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
GAITHERSBURG, Md., June 18 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that, in connection with the closing of the acquisition of MedImmune by AstraZeneca PLC pursuant to a...
Biotechnology Company Honored for Internal Launch of Productivity Tracking System GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that the company was...
GAITHERSBURG, Md., May 25 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that the U.S. Food and Drug Administration (FDA) has stated the agency has completed its review...
PLYMOUTH MEETING, Penn., May 24 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today reported that MedImmune, Inc. (NASDAQ:MEDI) presented data related to the Interleukin-9 (IL-9...
GAITHERSBURG, Md., May 16 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products...
New Economic Analyses of School and Daycare Study Outcomes Suggest Vaccinating Against Influenza May Produce Cost Savings for Community at Large TORONTO, May 8 /PRNewswire-FirstCall/...
- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections - TORONTO...
- Archana Singh, M.D., Winthrop University Hospital, Receives $35,000 Grant - TORONTO, May 7 /PRNewswire-FirstCall/ -- Underscoring its commitment to pediatric medicine, MedImmune, Inc...
- Victoria McMeen, M.D., University of Virginia, Receives $35,000 Grant - TORONTO, May 7 /PRNewswire-FirstCall/ -- Underscoring its commitment to pediatric medicine, MedImmune, Inc...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
